By disrupting the brain’s Default Mode Network, psilocybin has the potential to briefly unravel the rigid mental loops that define our sense of self. What emerges is both hopeful and unsettling: a glimpse of a mind freed from its own identity, and the realization that the “self” may be more fragile than once thought.
Tassneem Selman, Staff Writer
Photo source: Alexander De Foe, PhD; Sonya Gaber, PhD; and Daniel Perkins, PhD/Nature Publishing Group, via nature.com
Abstract digital illustration depicting a person immersed in swirling, cosmic forms, often associated with the psychedelic experience.
Most people fantasize about escape in geographical terms: a new city, a new job, a new “somewhere-else” where the noise finally quiets. But the loudest place we live isn’t a location – it’s our own head. The escape many people yearn for is internal: a momentary ceasefire from the constant narration of the self. With the rising popularity of psychedelics as a therapeutic alternative with less addictive potential than hard drugs among consumers intriguing researchers, exploration into this therapeutic phenomenon has been extensive. Neuroscientists call the network that generates that inner monologue the Default Mode Network (DMN) – the brain’s engine of stories, identity, and memory. And in recent years, a strange possibility has emerged from clinical labs and psychedelic research centers: what happens when that engine powers down?
The Machinery of “Being You”
For years, neuroscientists have treated the DMN as the core machinery behind the sense of self. Composed of the medial prefrontal cortex (mPFC), posterior cingulate cortex (PCC), precuneus, and angular gyrus, the DMN activates when attention turns inward: remembering the past, imagining the future, or replaying personal narratives (Scalabrini et al., 2023; Chou et al., 2023).
The network’s stability makes it essential for psychological continuity, integrating past experiences into a persistent sense of self. That stability, however, can become a liability. Research on individuals at risk for depression shows that heightened DMN connectivity correlates with rumination: repetitive, self-focused negative thinking that intensifies vulnerability to mental health disorders (Chou et al., 2023). In clinical scans, the DMN behaves less like a calm narrator and more like an echo chamber, looping self-referential thoughts until they harden into pathology. The DMN is not just where the self lives; it’s simultaneously a prison, where the self can get stuck.
What Psychedelics Actually Disrupt Classic psychedelics interfere with the DMN in ways that are visible using functional magnetic resonance imaging (fMRI). In neuroscience, functional connectivity refers to how strongly different brain regions communicate and synchronize their activity during specific mental states. Normally, the brain is organized into stable networks (like the DMN) that dominate during certain modes of cognition, such as self-reflection and autobiographical thinking.
Psilocybin disrupts this organization by reducing functional connectivity between key DMN hubs while increasing communication across the broader brain, effectively weakening the network’s internal cohesion (Gattuso et al., 2023). One of the most significant changes occurs between the mPFC and the PCC. These are two regions that form the structural and functional backbone of the DMN that are normally tightly coupled during normal self-referential thought, but under psilocybin, their connection decouples.
Early landmark studies documented widespread decreases in blood flow and activity within DMN regions, with particularly strong deactivation in the PCC (Carhart-Harris et al., 2012). More recent research confirms that psychedelics increase the global brain connectivity while disrupting the hierarchical organization that normally keeps the DMN dominant over other networks.
This pattern makes up the biological signature of ego dissolution: not just altered perception or hallucination, but a measurable weakening of the network responsible for maintaining the internal monologue. Simply put, psychedelics don’t just change what we see. They temporarily suspend the brain’s narrative authority, allowing for a loosening of rigid, self-referential thought – repetitive, inflexible patterns of thinking centered on the self.
The Existential and Therapeutic Consequences
When the DMN’s grip loosens, something strange happens: the psychological habits tied to it loosen too. Multiple studies link psychedelic experiences to reductions in rumination, a cognitive pattern deeply correlated to depression and anxiety (Barba et al., 2023). Users describe a release from rigid self-evaluation, a break in the loop that usually keeps them circling the same negative thoughts.
This change is not purely emotional. Psychedelic states are associated with measurable alterations in brain connectivity, including disrupted network integrity, linked to ego death and increases in brain connectivity accompanying loosening self-boundaries (Lebedev et al., 2015). In some cases, this ego reduction precedes decreases in depressive thinking weeks after the experience (Roseman et al., 2018). Another review notes that psychedelic states disrupt habitual patterns of self-focused processing, enabling more adaptive mental frameworks to emerge (Agin-Liebes et al., 2023).
Philosophically, the implications run deeper than symptom relief. If a molecule can quiet the self – soften it, dissolve it, or even make it momentarily irrelevant, what does that say about the nature of the self at all? Plato cast the soul as immutable, unified, and immortal (Plato, Phaedo 80b-81a; trans. 2018). However, neuroscience suggests something far more fluid: a self built from patterns of brain activity, a story the DMN keeps telling until something disrupts it. In other words, psychedelics expose the possibility that the self is not a fortress, but a dynamic process.
The Social Reality We Cannot Ignore
The scientific excitement around psychedelics exists within a social landscape shaped by criminalization, stigma, and inequity. The very substances now undergoing clinical trials were, for decades, used to prosecute and marginalize strategically undervalued communities. Today, in stark contrast, psychedelic-assisted therapy is becoming increasingly accessible only to those with economic and institutional privilege (dos Santos, R.G., et al. 2021).
At the same time, growing evidence suggests that psychedelics are not magic bullets. Their therapeutic potential depends heavily on context. Clinical trials impose strict conditions: substances are administered in controlled settings, paired with behavioral or psychotherapeutic support, and carefully monitored to reduce adverse reactions. Outside these environments, experiences can become disorienting or distressing, and so-called “bad trips” may undermine rather than enhance therapeutic outcomes. In other words, the same mechanisms that allow psychedelics to loosen rigid self-thinking can, in the wrong environment, destabilize it.
Despite documented benefits, including reductions in rumination, depression, and rigid patterns of self-thinking, access to regulated psychedelic care remains highly uneven. Legal constraints, high costs, and limited clinical infrastructure mean that those most vulnerable to mental health struggles often face the greatest risks with the least support. Without strong harm-reduction frameworks, therapeutic promise coexists with real potential for misuse and harm.
The ancient philosophical tradition reminds us that inquiry into the nature of the mind is inseparable from ethical duty (Plato). Neuroscience may explain how these substances work, but society decides who is protected, who is punished, and who is left behind.
The Uncertainties and the Temptation to Overreach
The promise of psychedelics is real, but the certainty is ambiguous. Much of the research connecting DMN disruption to therapeutic change is preliminary. It’s limited by small samples, untested assumptions, and unclear causal pathways (Gattuso, J. J., et al. 2023). Some findings are not replicable, while individual responses vary widely.
Clinically, psychedelic experiences can evoke anxiety, paranoia, resurfaced trauma, or psychological destabilization – all effects that have the potential to linger long after the drug leaves the body (Evans et al., 2023). Additionally, there’s a deeper existential risk: mistaking temporary escape for transformation, or becoming dependent on altered states rather than integrating a livable self.
Rethinking Freedom
If psychedelics allow us to briefly slip the boundaries of the self, that freedom also demands a broader sense of responsibility: to science, users, and to social systems that shape who gets access. The experience poses a philosophical challenge in which we must ask not only whether we can step outside ourselves, but what, exactly, we return to.
Perhaps the most radical insight is not that the self can disappear, but that it can change. The return of DMN function reasserts the brain’s narrative, though not always in the same shape. Psychedelics reveal that consciousness is elastic, that identity is neither fixed nor final, and that freedom may not begin with totally abandoning the self, but with understanding its impermanence.
The question, then, is no longer whether we can step outside ourselves for a moment. It’s what we choose to carry back with us when we return.
